

Ocular Photodynamic Therapy with Verteporfin for Macular Degeneration (#CAG-00066N)

Report from September 6, 2000 Meeting

- Subject:** Ocular Photodynamic Therapy (OPT) with Verteporfin
- Purpose:** Meet with interested parties from the ophthalmologic industry on the topic of age-related macular degeneration (AMD).
- Date:** September 6, 2000; 1:00 p.m.-2:00 p.m.
- Place:** Health Care Financing Administration (HCFA)
- Participants:** HCFA: Shana Olshan, Svati Patel, Poppy Rotter, Mike Londner, and Paul Rudolph.
Non-HCFA: James Rybicki and Randolph Fenninger.
- Summary:** This meeting was held to discuss the HCFA's coverage review (CAG-00066) of OPT with verteporfin. Presenters provided an overview of AMD and discussed the findings of the Treatment of AMD with Photodynamic Therapy (TAP) trial. The participants placed a strong emphasis on the importance of careful patient selection.
- Prepared by:** Svati Patel, CAG, OCSQ, HCFA; (410) 786-2875; spatel@cms.hhs.gov